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Abstract
Background
Imported strongyloidiasis is increasingly being diagnosed in non-endemic areas. The aim of
this study was to describe the epidemiological, clinical and microbiological characteristics of
patients with imported strongyloidiasis in Spain.
Methodology
This is an observational retrospective study that included all patients diagnosed of strongy-
loidiasis registered in the +REDIVI Collaborative Network from 2009 to 2017. Demographic,
epidemiological and clinical information was collected from the +REDIVI database, and
extra information regarding microbiological techniques, treatment and follow-up was
requested to participant centers.
Findings
Overall, 1245 cases were included. Most of them were immigrants (66.9%), and South
America was the most frequent area of origin. Detection of larvae in stool samples was
observed in 21.9% of the patients, and serological tests allowed making the diagnosis in the
rest of the cases. Eosinophilia was present in 82.2% of cases. Treatment with ivermectin
(compared with albendazole) was the most strongly associated factor to achieve the cure
(OR 2.34).
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Conclusions
Given the long latency of the infection and the risk of developing a severe presentation,
screening of S. stercoralis infection should be mandatory in patients coming from or had
traveling to endemic areas, especially in those with immunosuppressant conditions.
Author summary
Strongyloidiasis, the parasitic disease caused by the nematode Strongyloides stercoralis, is
being increasingly diagnosed in immigrant population in Spain. In the present study we
describe de clinical, epidemiological and microbiological profile of 1245 cases of imported
strongyloidiasis registered in the +REDIVI Spanish Collaborative Network. Patients were
mostly immigrants, and the majority of them were coming from South America. Serologi-
cal tests allowed the diagnosis in most of the cases, and detection of larvae in stool samples
was associated with male gender and presence of eosinophilia. Ivermectin was associated
with higher probability of cure compared with albendazole. Given the risk of developing a
severe presentation, screening of S. stercoralis infection should be mandatory in patients
coming from or had traveling to endemic areas, especially in those with immunosuppres-
sant conditions.
Introduction
Strongyloidiasis is caused by the soil-transmitted nematode Strongyloides stercoralis [1]. The
parasite is globally distributed in the tropics and occurs in some parts of the sub-tropics,
although it has also been reported in more temperate climates, like southern Europe and
North America [2]. It has been recently estimated that 370 million people are infected by the
parasite; however, this prevalence is most probably underestimated, since the majority of the
studies are focused on other soil-transmitted helminthes, and the microbiological techniques
commonly used have low sensitivity for S. stercoralis [3, 4].
S. stercoralis infection is most often asymptomatic, but patients may present with gastroin-
testinal, cutaneous, and respiratory symptoms [2]. This parasite has the unique ability to per-
sist in the human host for decades without the need of exogenous reinfection due to its
autoinfection life cycle. Nevertheless, some immunosuppressant conditions, such as corticoste-
roid therapy, solid organ or bone marrow transplantation and Human T-lymphotropic virus 1
(HTLV-1) infection, may amplify this autoinfective cycle, leading to severe presentations such
as the S. stercoralis hyperinfection syndrome and the disseminated strongyloidiasis [5, 6].
Due to increase of migrant flows and international travels during the last decades, imported
strongyloidiasis is being increasingly diagnosed in Spain, as well as in other non-endemic
areas, becoming a worldwide public health challenge [7–11]. The aim of the present study was
to describe the epidemiological, clinical and microbiological characteristics of patients with
imported strongyloidiasis registered in the +REDIVI Spanish Collaborative Network, as well
as to identify potential factors related to parasite burden and treatment success.
Material and methods
Study design and study population
This is an observational retrospective study that included all patients diagnosed of strongyloi-
diasis registered in the +REDIVI Collaborative Network from January 2009 to February 2017.
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This Spanish network includes 22 centers which share a common online database to register
epidemiological and clinical information of immigrants and travelers who attend these centers.
The database includes: demographic information (date of birth, gender, and country of birth),
epidemiological data (country of origin for immigrants, travel characteristics), and clinical
information (main reason for consultation, and diagnosis). +REDIVI includes 4 types of
patients: immigrants (people living in Spain and born in other country), Visiting Friends and
Relatives (VFR)-immigrants (immigrants who have travelled to their country of birth to visit
friends and relatives), VFR-travelers (people born in Spain who have travelled to their first-
degree relative’s country of birth), and travelers (people born in Spain who return from inter-
national travels).
All participant centers were requested to contribute with extra information from the
included patients: HTLV-1 co-infection, eosinophil cell count at diagnosis, microbiological
techniques performed and their results, treatment information, and follow-up controls up to
two visits.
Microbiological techniques
Stool microscopic examination was performed using the Ritchie’s formalin-ether technique in
all centers. The specific fecal culture for S. stercoralis larvae was performed using the agar plate
or charcoal technique. Detection of serum anti-S. stercoralis IgG was performed through dif-
ferent enzyme-linked immunosorbent assay (ELISA)-based commercial kits depending on the
center: SciMedx Strongyloides serology microwell ELISA (SciMedx Corporation, Denville, NJ,
United States), NovaLisa Strongyloides (NovaTec Immunodiagnostica GmbH, Dietzenbach,
Germany), Strongyloides IgG IVD-ELISA (DRG Instruments GmbH, Marburg, Germany),
AccuDiag Strongyloides IgG ELISA Kit (Diagnostic Automotion/Cortez Diagnostics Inc, CA,
United States). All serological tests were performed and cut-off of the optical density values to
determine a positive result was established following manufacturer instructions.
Definitions
Eosinophilia was defined as eosinophil cell count� 0.45x109cells/L and/or a percentage�5%:
mild (<1.0x109cells/L), moderate (1.0–3.0x109cells/L), and severe (>3.0x109cells/L). The S.
stercoralis infection diagnosis was classified into three groups: definite (detection of larvae by
any parasitological technique), probable (positive serological result and presence of eosino-
philia), and possible (positive serological result without presence of eosinophilia). We consid-
ered severe clinical presentation: hyperinfection syndrome (infection confined to lungs and
gastrointestinal tract, but symptoms of severe disease related to elevated number of larvae) and
disseminated strongyloidiasis (larvae found in any organ other than the lungs and gastrointes-
tinal tract). In order to evaluate the treatment outcome, four categories were considered. The
“cure” criteria was established when patients had negative conventional methods (microscopic
stool examination and/or fecal culture) after treatment, disappearance of the eosinophilia, and
negative serology (or at least a 60% decrease in the OD ratio) during follow-up (independently
of the time they reached this situation). We established “probable cure” criteria when the cure
criteria were reached but eosinophilia persisted (because it could be to other cause) or when in
the absence of serologic control, patients had negative conventional methods after treatment
and disappearance of the eosinophilia. “Failure” was considered if larvae were detected after
the treatment or when the cure or probable cure criteria regarding serology were not reached
during follow-up (with a minimum of 6 months of follow-up). The outcome “not enough
information” was considered when the patients had negative conventional methods after
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treatment, but cure or probable cure criteria regarding eosinophilia and serology were not
reached during follow-up (with a follow-up period less than 6 months).
Statistical analysis and ethical issues
The STROBE statement guidelines were used to improve the quality of the study [12]. Proce-
dures were performed in accordance with the ethical standards laid down in the Declaration of
Helsinki as revised in 2013, and the study protocol was approved by the Ethical Review Board
of the Vall d’Hebron University Hospital (Barcelona, Spain). The Ethical Review Board was
consulted, and agreed that informed consent was not necessary given de retrospective nature
of the study and the anonymization of the information.
Categorical data are presented as absolute numbers and proportions, and continuous vari-
ables are expressed as means and standard deviations (SD) or medians and interquartile ranges
(IQR) depending on the distribution. The Kolmogorov-Smirnov test was used to evaluate the
normal distribution of variables. The χ2 test or Fisher exact test, when appropriate, was used to
compare the distribution of categorical variables, and the t-Student test for continuous vari-
ables. Multivariate logistic regression analysis was made to identify factors associated with con-
firmed diagnosis and cure. Variables were entered in the model if p<0.20 on univariate
analysis. Results were considered statistically significant if the 2-tailed P value was <0.05. SPSS
software for Windows (Version 19.0; SPSS Inc, Chicago, IL, USA) was used for statistical
analyses.
Results
Overall, 12796 patients were registered in +REDIVI from January 2009 to February 2017. Of
these, 1279 patients had the S. stercoralis infection diagnosis. After revising these cases, 34
patients were withdrawn due to erroneous codification or duplication; hence, resulting in 1245
(9.7%) patients with S. stercoralis infection diagnosis (Fig 1). The mean age at the time of diag-
nosis was 38.3 (SD 12.9) years, and 590 (47.4%) were men (see Table 1). Most of them were
immigrants (833 patients, 66.9%), and 80 (6.4%) patients had some kind of immunosuppres-
sant condition. The main reasons for consultation were “laboratory test alteration” (41.1%)
and “health screening” (39.4%). Only 5 (0.4%) patients had the diagnosis of hyperinfection
syndrome: two patients with autoimmune diseases who were receiving immunosuppressive
therapies (including corticosteroids), one patient with HTLV-1 infection, one patient with
HIV infection, and one patient without any immunosuppressant condition. Six hundred and
five (48.6%) patients had at least another infectious disease at the time of strongyloidiasis diag-
nosis, being Chagas disease (21.8%), latent tuberculosis infection (6%), and schistosomiasis
(5%) the most prevalent ones (S1 Table).
Among the 833 immigrants, South America was the most frequent geographical area of ori-
gin, and mean time of residence in Spain was 6.8 (SD 5.4) years. The median duration of the
trip in travelers and VFR-immigrants were 45 (IQR 19.7–227) days and 30 (IQR 30–60) days
respectively, and Sub-Saharan Africa and South America were the most frequent geographical
areas of travel destination (S2 Table).
After requesting extra information of the included patients to the participant centers, it was
available from 1062 (85.3%) patients. Regarding S. stercoralis infection diagnosis, patients
could be classified as follows: definite in 233 (21.9%) patients, probable in 648 (61%) patients,
and possible in 181 (17.1%) patients. Proportion of positive results for each microbiological
technique was: 17.4% for stool formalin-ethyl acetate sedimentation, 22.5% for S. stercoralis
fecal culture, and 98.8% for S. stercoralis serology. These differences were higher when analyz-
ing the efficiency of the microbiological techniques in the 561 patients in whom all three
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techniques were performed (see Table 2). Nine hundred and sixty-eight patients received spe-
cific treatment for strongyloidiasis; 94 patients did not return to the centers after the diagnosis,
and treatment could not be offered to them. Ivermectin was the drug of choice in 90.4% of the
cases. From the 968 patients who received treatment, 784 (81%) had at least one follow-up con-
trol, with median time of follow-up of 6 (IQR 3–11) months. Treatment outcomes of these
patients were as follows: 301 (38.4%) cure, 350 (44.6%) probable cure, 54 (6.9%) treatment
Fig 1. Flow diagram of patients.
https://doi.org/10.1371/journal.pntd.0007399.g001
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failure, and 79 (10.1%) with no enough information. From the 54 patients considered treat-
ment failure, only in four cases was due to larvae detection after treatment: a 40-years-old man
coming from Sudan (treated with 200mcg/day x 2days, larvae detected after 4 months), a
28-years-old women coming from Bolivia (treated with 200mcg/day x 2days, larvae detected
after 6 months), a 35-years-old women coming from Equatorial Guinea (with HIV infection,
treated with 200mcg/day x 2days, larvae detected after 3 months), and a 43-years-old man
coming from Bolivia (treated with albendazole 400mg/12 hours x 7 days, larvae detected after
3 months). Therefore, 83% of the patients achieved a successful outcome (cure or probable
cure). More information regarding the treatment and follow-up results is summarized in
Table 3 and S3 Table.
When analyzing potential factors associated with having a definite diagnosis, after the mul-
tivariate analysis, the presence of eosinophilia was the most strongly associated factor, with an
OR of 3.83 (95%CI 2.09–7.04). Presence of moderate/severe eosinophilia and male gender
were also associated with confirmed diagnosis, with an OR of 1.57 (95%CI 1.15–2.14) and 1.69
(95%CI 1.25–2.29) respectively. Conversely, the immigrant group (compared with VFR-immi-
grants and travelers) had a negative association with definite diagnosis, with an OR of 0.64
(95%CI 0.47–0.87). More information is depicted in Table 4. Regarding factors associated to
Table 1. Clinical and demographic characteristics of patients with strongyloidiasis in +REDIVI (2009–2017).
Clinical and demographic characteristics Number of patients (n = 1245)
Demographic information
Age, years 38.3 (SD 12.9, 2–88)
Gender, male 590 (47.4%)
Epidemiological groups
Immigrants 833 (66.9%)
VFR-immigrants 338 (27.1%)
Travelers 74 (6%)
Immunosuppressant conditions
None 1165 (93.6%)
HIV infection 55 (4.4%)
Immunosuppressive drugs 15 (1.2%)
Organ transplantation 5 (0.4%)
Other 5 (0.4%)
Main reason for consultation
Laboratory test alteration 512 (41.1%)
Health screening 491 (39.4%)
Gastrointestinal symptoms 105 (8.4%)
Cutaneous manifestations 105 (8.4%)
Fever 33 (2.7%)
Respiratory symptoms 9 (0.7%)
Bone/muscle manifestations 8 (0.6%)
Cardiovascular symptoms 7 (0.6%)
Lymphadenopathy 4 (0.3%)
Other 17 (1.4%)
Clinical presentation
Non-complicated strongyloidiasis 1240 (99.6%)
Hyperinfection syndrome 5 (0.4%)
NOTE. Data are reported as number (%) of patients or mean (SD, range)
https://doi.org/10.1371/journal.pntd.0007399.t001
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achieving the cure criteria, treatment with ivermectin (compared with treatment with albenda-
zole) was the most strongly associated factor, with an OR of 2.34 (95%CI 1.23–4.47). Male gen-
der, presence of eosinophilia, and definite diagnosis had a negative association for achieving
the cure criteria (see Table 5).
Table 2. Laboratorial and microbiological information at the time of diagnosis of patients with strongyloidiasis in +REDIVI with available extra information
(2009–2017).
Laboratory and microbiology
information of all patients
Number of patients
(n = 1062)
Laboratory and microbiology information of patients in whom all three
microbiological techniques were performed
Number of patients
(n = 561)
Presence of eosinophilia 867/1055 (82.2%) Positive microbiological techniques
Mild (<1.0x109cells/L) 490/867 (56.5%) Stool microscopic investigation 52/561 (9.3%)
Moderate (1.0–3.0x109cells/L) 356/867 (41.1%) S. stercoralis specific faecal culture 84/561 (15%)
Severe (>3.0x109cells/L) 21/867 (2.4%) S. stercoralis serology 554/561 (98.8%)
HTLV-1 infection 9 /224 (4%) Patients with positive results in all techniques 40/561 (7.1%)
S. stercoralis infection diagnosis Patients with 2 positive results 49/561 (8.8%)
Definite 233/1062 (21.9%) Serology + culture 37/561 (6.6%)
Probable 648/1062 (61%) Serology + microscopic investigation 8/561 (1.5%)
Possible 181/1062 (17.1%) Culture + microscopic investigation 4/561 (0.7%)
Positive microbiological techniques Patients with only 1 positive result 472/561 (84.1%)
Stool microscopic investigation 173/995 (17.4%) Serology 469/561 (83.6%)
S. stercoralis specific faecal culture 145/643 (22.5%) Culture 3/561 (0.5%)
S. stercoralis serology 935/946 (98.8%) Microscopic investigation 0/561 (0%)
NOTE. Data are reported as number (%) of patients.
https://doi.org/10.1371/journal.pntd.0007399.t002
Table 3. Treatment and follow-up information of patients with strongyloidiasis in +REDIVI with available extra information (2009–2017).
Drug of choice (n = 968) Duration of the treatment Follow-up (n = 968)
Ivermectin 875
(90.4%)
Duration for ivermectin
(n = 884)
Number of follow-up controls
150mcg/Kg/day po 94 (9.7%) 1 day 31 (3.5%) No control 184 (19%)
200mcg/Kg/day po 780
(80.6%)
2 days 840 (95%) One control 520 (53.7%)
200mcg/Kg/day po+sc 1 (0.1%) 4 days 9 (1%) Two controls 264 (27.3%)
Albendazole 400mg/12 hours po 84 (8.7%) 7 days 3 (0.4%) Mean time of follow-up,
months
6 (IQR
3–11)
Ivermectin 200mcg/Kg/day po + albendazole 400mg/12
hours
9 (0.9%) 20 days 1 (0.1%) Treatment outcome (n = 784)
Duration for albendazole
(n = 93)
Cure 301 (38.4%)
3 day 5 (5.4%) Probable cure 350 (44.6%)
5 days 34
(36.6%)
Treatment failure 54 (6.9%)
6 days 1 (1.1%) No enough information 79 (10.1%)
7 days 48
(51.6%)
8 days 1 (1.1%)
10 days 2 (2.1%)
15 days 2 (2.1%)
NOTE. Data are reported as number (%) of patients or median (IQR). Po, peroral; sc, subcutaneous.
https://doi.org/10.1371/journal.pntd.0007399.t003
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Discussion
Imported strongyloidiasis is increasingly being diagnosed in non-endemic countries, espe-
cially in Spain, who receives an important number of immigrants coming from endemic areas,
although information comes from short series of cases [7–11]. Here we present a cohort of
1245 patients with imported strongyloidiasis in Spain: most of them were asymptomatic immi-
grants coming from South America, 82.2% had eosinophilia at the time of diagnosis, 6.4% of
Table 4. Factors associated to definite diagnosis in patients with strongyloidiasis in +REDIVI with available extra information (2009–2017).
Overall (n = 1062) Definite diagnosis
(n = 233)
Probable diagnosis
(n = 829)
Univariate
analysis
(P value)
Multivariate analysis
(OR, 95%CI, and P value)
Mean age at diagnosis, years 37.9 (SD 13.04,
2–88)
39.4 (SD 12.7, 2–88) 37.5 (SD 13.1, 2–82) 0.058 OR 1.01 (0.99–1.02),
p = 0.181
Gender, male 520/1062 (49%) 136/233 (58.4%) 384/829 (46.3%) 0.001 OR 1.69 (1.25–2.29),
p = 0.001
Immigrantsa 699/1062 (65.8%) 136/233 (58.4%) 563/829 (67.9%) 0.007 OR 0.64 (0.47–0.87),
p = 0.006
Time of residence in Spain, years
(n = 699)b
6.4 (SD 5.1, 0–34) 5.6 (SD 4.3, 0–21) 6.5 (SD 5.2, 0–34) 0.050 -
Presence of immunosuppressant
condition
71/1062 (6.7%) 13/233 (5.6%) 58/829 (7%) 0.444 -
HTLV-1 co-infection (n = 224) 9/224 (4%) 3/55 (5.5%) 6/169 (3.6%) 0.692 -
Presence of eosinophilia (n = 1055) 867/1055 (82.2%) 219/232 (94.4%) 648/823 (78.7%) <0.001 OR 3.83 (2.09–7.04),
p<0.001
Moderate/Severe eosinophilia
(n = 1055)
377/1055 (35.7%) 113/232 (48.5%) 264/823 (32.1%) <0.001 OR 1.57 (1.15–2.14),
p = 0.004
Presence of symptomsc 190/1062 (17.9%) 40/233 (17.2%) 150/829 (18.1%) 0.744 -
NOTE. Data are reported as number (%) of patients or mean (SD, range).
a Immigrant group compared to VFR-immigrants and travelers.
b Time of residence in Spain in immigrant patients.
c Patients in whom the main reason for consultation were not laboratory test alteration nor health screening.
https://doi.org/10.1371/journal.pntd.0007399.t004
Table 5. Factors associated to cure in patients with strongyloidiasis in +REDIVI with available extra information (2009–2017).
Overall (n = 705)a Cure (n = 301) Not cure (n = 404) Univariate analysis
(P value)
Multivariate analysis
(OR, 95%CI, and P value)
Mean age at diagnosis, years 39.8 (SD 12.8, 2–88) 40 (SD 12.5, 5–71) 39.2 (SD 13.1, 2–88) 0.132 OR 1.01 (0.99–1.02), p = 0.132
Gender, male 344/705 (48.8%) 130/301 (43.2%) 214/404 (53%) 0.010 OR 0.64 (0.47–0.88), p = 0.007
Presence of immunosuppressant condition 50/705 (7.1%) 27/301 (9%) 23/404 (5.7%) 0.094 OR 1.37 (0.73–2.56), p = 0.314
HTLV-1 co-infection (n = 152) 7/152 (4.6%) 4/105 (3.8%) 3/47 (6.4%) 0.677 -
Presence of eosinophilia (n = 704) 608/704 (86.4%) 241/301 (80.1%) 367/403 (91.1%) <0.001 OR 0.49 (0.30–0.78), p = 0.003
Moderate/Severe eosinophilia (n = 704) 268/704 (38.1%) 107/301 (35.5%) 161/403 (39.9%) 0.234 -
Definite diagnosis 178/705 (25.2%) 50/301 (16.6%) 128/404 (31.7%) <0.001 OR 0.44 (0.30–0.64), p<0.001
Presence of symptomsb 122/705 (17.3%) 63/301 (20.9%) 59/404 (14.6%) 0.028 OR 1.42 (0.73–2.56), p = 0.094
Treatment with ivermectin (n = 698) c 644/698 (92.3%) 285/299 (95.3%) 359/399 (90%) 0.009 OR 2.34 (1.23–4.47), p = 0.009
NOTE. Data are reported as number (%) of patients or mean (SD, range).
a Patients with not enough information to establish the treatment outcome were withdrawn from the analysis.
b Patients in whom the main reason for consultation were not laboratory test alteration nor health screening.
c Patients were only analyzed when treated with a single drug (ivermectin or albendazole).
https://doi.org/10.1371/journal.pntd.0007399.t005
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them had some kind of immunosuppressant condition, almost half of them had another infec-
tious disease (being Chagas disease the most frequent one), serology allowed the diagnosis in
most of the cases, and treatment with ivermectin was associated with better outcome.
It is important to note that, although the percentage of patients with eosinophilia was very
high (more than 80%), the eosinophilia could be due to other causes, since there were patients
co-infected with other helminthiases such as schistosomiasis, soil-transmitted helminths, or
filarial nematodes. Hence, the percentage of patients with eosinophilia could be overestimated.
As in other imported strongyloidiasis series, most of the cases were diagnosed in immi-
grants and VFR-immigrants [7–11]. It is important to note that strongyloidiasis in VFR may
have been acquired prior to residence in Spain rather than during the recent travel to their
country of origin. Strongyloidiasis in travelers, although described, is much more infrequent,
and restricted to high risk travelers, such as long-term travelers, humanitarian workers, and
backpackers. In a study performed in The Netherlands where 679 asymptomatic long-term
travelers to the tropics (median travel duration of 12 weeks) were post-travel screened for
intestinal parasites using molecular techniques, only one (0.1%) traveler was diagnosed of
strongyloidiasis [13]. In our study, travelers represented 6% of the total study population,
which is higher than in other studies; it could be due to the epidemiological profile of travelers
registered in +REDIVI, with high percentage of high risk travelers (missionaries and humani-
tarian workers). Among immigrants and VFR-immigrants, South America was the most fre-
quent geographical area of origin, which is concordant with the general immigrant population
in Spain, probably due to cultural and historic reasons. Spanish Tropical Medicine Units are
highly sensitized in offering Chagas disease screening in South American population, espe-
cially those coming from Bolivia. This is the reason of the high proportion of patients coming
from Bolivia in our study, and the high proportion of Chagas disease-strongyloidiasis co-infec-
tion. This co-infection has been recently found to increase the likelihood to detect Trypano-
soma cruzi DNA in peripheral blood, which may reflect the potential immunomodulatory
effects of S. stercoralis infection [14].
The percentage of severe clinical manifestations in our study (0.4%) could be underesti-
mated, since most of the patients were referred to the centers for screening their health status
or eosinophilia investigation. From the five patients with hyperinfection syndrome, four had
some immunosuppressant risk factor (80%), whereas only 6% of patients without hyperinfec-
tion syndrome were immunosuppressed. Two of them were receiving corticosteroids, which
was the most related risk factor found in a recent systematic review that included 244 cases of
severe strongyloidiasis [6]. HTLV-1 infection increases the risk of S.stercoralis infection, the
risk of developing a severe strongyloidiasis, and the risk of treatment failure [15]. In our study,
9 patients had a positive HTLV-1 serological test (one of them presenting a severe strongyloi-
diasis), although the test was only performed in 224 patients (21% of the study population).
There is currently no gold standard for S. stercoralis infection diagnosis, since the available
techniques are not sensitive enough. Larvae detection in stool or other samples gives a definite
diagnosis, but the scarce and irregular larvae excretion in chronically infected patients makes
the diagnosis challenging. Although parasitological techniques have been improving (concen-
tration techniques, Harada-Mori, Baermann, fecal culture), these techniques are not sensitive
enough [16, 17]; in our study, the proportion of positive results in patients in whom all three
techniques were performed was 9.3% for the formalin-ether technique and 15% for the fecal
culture. The presence of eosinophilia was strongly associated with higher proportion of defi-
nite diagnosis, which may reflect a higher larvae excretion, possibly related to a higher parasite
burden in these patients. Male gender was also associated with definite diagnosis. Both factors
have been previously associated with Strongyloides infection in studies where the infection was
defined by positive parasitological techniques [18, 19]. Conversely, being immigrant had a
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negative association with definite diagnosis. It could be explained due to the chronic situation
of the infection in this group of patients (they have leaved the endemic region years ago), and
the fact that many of them have been diagnosed during a health screening, without presenting
neither symptoms nor eosinophilia. In recent years, DNA detection-based techniques (such as
PCR) have been developed, showing higher sensitivity than classical parasitological techniques
[20].
Fortunately, different serological techniques have been developed during the last decades in
order to increase the sensitivity in the strongyloidiasis diagnosis, being the ELISA-based tech-
niques the ones with highest sensitivity [21]. Previous studies have shown the usefulness of S.
stercoralis serology in the diagnosis of strongyloidiasis, especially in those presenting eosino-
philia with negative coproparasitological examination [8, 22]. Serology allowed strongyloidia-
sis diagnosis in 78.1% of the patients in our study, becoming a key tool in the management of
these patients. Moreover, serological tests are also useful to evaluate the treatment response,
although a uniform criterion to define cure has not yet been established. In general, a negative
serology or a 50–60% decrease in the optical density after treatment is considered a cure crite-
ria or a successful outcome, which was the criteria used in the present study, although the time
when this decrease should be determined is not well established [8, 23–25]. Nevertheless, S.
stercoralis serology may overestimate the prevalence of strongyloidiasis, since it may remain
positive after resolution of the infection or could cross-react with other helminth infections. It
has been suggested that increasing the cut-off value for positive serology may increase the spec-
ificity of the serological test in the diagnosis of confirmed strongyloidiasis [26]. Other diagnos-
tic strategy could include a combination of different techniques, such as classical
parasitological methods, serology, and even PCR.
Some clinical trials have compared the efficacy between ivermectin and albendazole for the
treatment of chronic strongyloidiasis, with a cure rate ranging from 76% to 98% and 38% to
78% respectively. All these clinical trials included a relative low number of subjects, used differ-
ent treatment schemes and dosages, and assessed the treatment success using classical parasito-
logical methods. As mentioned before, this strategy may have overestimated the cure response
due to lack of sensitivity [27–32]. A recent Cochrane review has performed a meta-analysis
comparing the efficacy of ivermectin versus albendazole including 478 participants, showing
higher parasitological cure with ivermectin (RR 1.79, 95%CI 1.55–2.08) with moderate quality
evidence [33]. Although our study had a retrospective design, a high number of patients (698
participants) could be evaluated to compare the efficacy of ivermectin versus albendazole; and
more interestingly, our study included serological techniques during the follow-up, that
increases the possibility to detect treatment failures. Even though the evidence of ivermectin
superiority, almost 10% of the patients in our study were treated with albendazole; it could be
explained because most of these cases took place at the beginning of the study (the evidence
was less than nowadays), and the availability of ivermectin in some Spanish regions is limited.
Patients with eosinophilia or with definite diagnosed were less likely to achieve the cure crite-
ria; although it could reflect higher parasitic load in these patients, the retrospective nature of
the study makes difficult the interpretation of these results. Male gender was also negatively
associated to cure, which has been previously described in other studies [30].
The results of the previously mentioned clinical trials are very different to and contradict
with the results of a recent observational study performed in a non-endemic area (Buenos
Aires, Argentina). In this study, 21 patients with strongyloidiasis were treated with ivermectin;
during follow-up, in 14 patients larvae were detected in stools by conventional methods, and S.
stercoralis DNA was detected by PCR in all patients [34]. Although these results are surprising,
they should be taken with caution, since come from a small observational study, and stronger
evidence (coming from clinical trials) shows high efficacy of ivermectin. In our study, although
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79 patients were considered treatment failure, only in 4 patients larvae were detected by con-
ventional methods. Management of strongyloidiasis treatment failure is not standardized; the
general attitude of the participant centres in our study in these situations was to repeat a course
of ivermectin or to treat with a long course of albendazole.
This study has some limitations given its retrospective nature. Patients were diagnosed
through different serological tests, and information regarding the number of stool samples
tested in each patient was not collected, and it could influence in the sensitivity of fecal-based
diagnostic techniques. Diagnostic tests and time of evaluation during follow-up were different
depending on the centre. Moreover, the number of patients treated with albendazole was very
low, and it difficult the interpretation of the efficacy comparison between the two drugs.
Hence, the results have to be interpreted with caution. Despite these limitations, the present
study has very strong points, such as the high number of included patients, the participation of
22 centers distributed through different Spanish regions, and reflects how Tropical Medicine
specialists diagnose and manage patients with strongyloidiasis in a non-endemic setting under
real conditions. The collaborative networks, such as the Spanish +REDIVI network, give the
possibility to gather information from high number of patients, being very useful to study
some rare manifestations from common diseases [35]. It will allow us to further investigate sit-
uations such as severe strongyloidiasis or strongyloidiasis in immunosuppressed patients.
In summary, we present a cohort of 1245 patients with imported strongyloidiasis in Spain.
Patients were mostly immigrants, and the majority of them were coming from South America.
Serological tests allowed the diagnosis in most of the cases, and detection of larvae in stool
samples was associated with male gender and presence of eosinophilia. Ivermectin was associ-
ated with higher probability of cure compared with albendazole. Given the risk of developing a
severe presentation, screening of S. stercoralis infection should be mandatory in patients com-
ing from or had traveling to endemic areas, especially in those with immunosuppressant con-
ditions [36]. Although parasitological techniques are the only that can confirm the diagnosis,
to include serological techniques is very useful both at diagnosis and follow-up. Whenever pos-
sible, ivermectin must be the drug of choice. And finally, given the high number of immigrants
and travelers coming from endemic areas that live in Spain, although unlikely under current
hygienic conditions, reintroduction of the disease in our country could potentially occur,
which would have important public health implications.
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